Vonoprazan is superior to proton pump inhibitors in healing artificial ulcers of the stomach post-endoscopic submucosal dissection: A propensity score-matching analysis

Dig Endosc. 2017 Jan;29(1):57-64. doi: 10.1111/den.12705. Epub 2016 Sep 5.

Abstract

Background and aim: Proton pump inhibitors (PPI) are effective at healing artificial ulcers after endoscopic submucosal dissection (ESD) for gastric neoplasms; however, the efficacy of vonoprazan is not completely understood. The aim of the present study was to determine the healing effect of vonoprazan on artificial ulcers post-gastric ESD relative to PPI.

Methods: Thirty-five patients who underwent gastric ESD between April and November 2015 were treated with vonoprazan 20 mg/day for 4 weeks and subsequently underwent endoscopy for evaluation of ulcer size (V group). Ulcer contraction rate was determined by the following formula: ([ESD specimen size] - [ulcer size at 4 weeks after ESD])/(ESD specimen size) × 100%. We compared the results with those of a historical control group treated with esomeprazole 20 mg/day for 4 weeks after gastric ESD and subsequently measured their ulcer size (33 patients, E group) by propensity score-matching methods.

Results: Sixty-two subjects were enrolled after propensity score-matching. Ulcer contraction rate at 4 weeks after ESD in the V group was significantly higher than that of the E group (97.7 ± 3.2% vs 94.5 ± 6.7%, respectively, P = 0.025). Number of subjects with a scar-stage ulcer (100% contraction rate) tended to be higher in the V group relative to the E group (32% [10 of 31] vs 13% [4 of 31], respectively, P = 0.070, McNemar's chi-squared test).

Conclusion: Vonoprazan has a faster post-gastric ESD artificial ulcer contraction rate than esomeprazole. Vonoprazan may supersede PPI in treating post-ESD artificial ulcers of the stomach.

Keywords: artificial ulcer; endoscopic submucosal dissection; gastric carcinoma; proton pump inhibitor; vonoprazan.

MeSH terms

  • Aged
  • Endoscopic Mucosal Resection / adverse effects*
  • Esomeprazole / therapeutic use*
  • Female
  • Follow-Up Studies
  • Gastroscopy
  • Humans
  • Male
  • Postoperative Complications / diagnosis
  • Postoperative Complications / drug therapy*
  • Postoperative Complications / etiology
  • Propensity Score*
  • Prospective Studies
  • Proton Pump Inhibitors / therapeutic use
  • Pyrroles / therapeutic use*
  • Stomach Neoplasms / surgery*
  • Stomach Ulcer / diagnosis
  • Stomach Ulcer / drug therapy*
  • Stomach Ulcer / etiology
  • Sulfonamides / therapeutic use*
  • Treatment Outcome

Substances

  • 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine
  • Proton Pump Inhibitors
  • Pyrroles
  • Sulfonamides
  • Esomeprazole